Bausch + Lomb Corp's stock took a hit today, closing down 2.04% as investors react to recent developments.
In the latest trading session, Bausch + Lomb Corp (BLCO.TO) experienced a decline of 2.04%, closing at CA$20.61. This drop comes amid ongoing concerns about the company's financial performance and recent strategic moves.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.16B
52W high
$25.70
52W low
$18.24
1W change
-5.71%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.6% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.92
-17.6% Upside
Current Price
C$22.96
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
31.1%
Annualized
Trend (90d)
+2.8%
Annualized drift
90d Mean
C$23.19
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$23.04 | C$20.56 โ C$25.81 |
| 60 trading days | C$23.11 | C$19.68 โ C$27.14 |
| 90 trading days | C$23.19 | C$19.05 โ C$28.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Bausch + Lomb's financial health and strategic initiatives as the company navigates challenges in the ophthalmic market.
Bausch + Lomb Corp's stock down 2.04% today
With a market cap of approximately CA$7.5 billion, Bausch + Lomb's recent performance reflects investor caution amid financial uncertainties.
Bull case
Bausch + Lomb's investment in Emmecell's innovative magnetic cell delivery technology could set the stage for future growth in the ophthalmic sector. This technology addresses significant clinical needs and could enhance the company's offerings.
Bear case
The company's current negative profit margin and lack of a dividend yield raise concerns about its financial stability and ability to generate returns for shareholders.
Recent Performance and Market Reaction
Bausch + Lomb's stock decline of 2.04% reflects investor sentiment amid concerns about the company's financial health. With a market cap nearing CA$7.5 billion, the stock's performance is indicative of broader market apprehensions regarding profitability and growth potential.
Strategic Moves and Future Outlook
The company's recent investment in Emmecell, aimed at advancing innovative treatment options for ophthalmic diseases, could provide a pathway for future growth. However, the lack of profitability and dividend yield raises questions about the sustainability of such investments. Investors should keep an eye on how these strategic moves unfold in the coming quarters. For more insights, check out our detailed analysis on Bausch + Lomb Corp.
Advertisement
